HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 2611人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308588, encodeId=bb67130858889, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, objectType=article, longId=204512, objectId=cc0e204512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0e204512c6, replyNumber=0, likeNumber=36, createdTime=2020-12-16, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0e204512c6, moduleTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0e204512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308587, encodeId=4f58130858e2d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=突破！乳腺癌疫苗GP2研究发现对HER2阳性乳腺癌术后，5年无一复发！, objectType=article, longId=204448, objectId=399220444833, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=399220444833, replyNumber=0, likeNumber=62, createdTime=2020-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=399220444833, moduleTitle=突破！乳腺癌疫苗GP2研究发现对HER2阳性乳腺癌术后，5年无一复发！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=399220444833)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308586, encodeId=27b5130858679, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, objectType=article, longId=203556, objectId=4991203556ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4991203556ab, replyNumber=0, likeNumber=42, createdTime=2020-11-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4991203556ab, moduleTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4991203556ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308585, encodeId=c6bf1308585bc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌, objectType=article, longId=202248, objectId=6763202248e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6763202248e2, replyNumber=0, likeNumber=36, createdTime=2020-10-19, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6763202248e2, moduleTitle=Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6763202248e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308584, encodeId=b400130858457, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, objectType=article, longId=200277, objectId=dacc2002e766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacc2002e766, replyNumber=0, likeNumber=31, createdTime=2020-09-06, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacc2002e766, moduleTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacc2002e766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308583, encodeId=a6ba1308583b9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, objectType=article, longId=199921, objectId=e4ad199921fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ad199921fd, replyNumber=0, likeNumber=40, createdTime=2020-08-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ad199921fd, moduleTitle=抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ad199921fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308582, encodeId=74d9130858252, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, objectType=article, longId=199369, objectId=112e19936941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112e19936941, replyNumber=0, likeNumber=26, createdTime=2020-08-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112e19936941, moduleTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112e19936941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308581, encodeId=a234130858144, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, objectType=article, longId=199343, objectId=af9d1993432d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9d1993432d, replyNumber=0, likeNumber=30, createdTime=2020-08-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d1993432d, moduleTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9d1993432d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308580, encodeId=bacf1308580d2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Nat Commun：HER2阳性乳腺癌在双HER2阻断期间和之后的表型变化, objectType=article, longId=198574, objectId=90961985e4c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90961985e4c3, replyNumber=0, likeNumber=28, createdTime=2020-08-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90961985e4c3, moduleTitle=Nat Commun：HER2阳性乳腺癌在双HER2阻断期间和之后的表型变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90961985e4c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308579, encodeId=e1b213085e9f6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果, objectType=article, longId=198092, objectId=8f48198092eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f48198092eb, replyNumber=0, likeNumber=29, createdTime=2020-07-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f48198092eb, moduleTitle=Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f48198092eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308578, encodeId=ce3f13085e847, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著, objectType=article, longId=196097, objectId=c0f719609e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f719609e16, replyNumber=0, likeNumber=37, createdTime=2020-06-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f719609e16, moduleTitle=NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f719609e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308577, encodeId=8f6d13085e74e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, objectType=article, longId=194729, objectId=8973194e294c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8973194e294c, replyNumber=0, likeNumber=36, createdTime=2020-05-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8973194e294c, moduleTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8973194e294c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308576, encodeId=5f1913085e6b9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=范志民教授专访：T-DM1治疗HER2阳性non-pCR乳腺癌面面观, objectType=article, longId=194536, objectId=26a8194536be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26a8194536be, replyNumber=0, likeNumber=42, createdTime=2020-05-23, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26a8194536be, moduleTitle=范志民教授专访：T-DM1治疗HER2阳性non-pCR乳腺癌面面观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26a8194536be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308575, encodeId=a6a313085e5fb, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=35, createdTime=2020-05-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308574, encodeId=40e913085e4f8, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=28, createdTime=2020-05-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308573, encodeId=d97113085e37d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, objectType=article, longId=194124, objectId=c8f2194124ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8f2194124ca, replyNumber=0, likeNumber=40, createdTime=2020-05-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8f2194124ca, moduleTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8f2194124ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308572, encodeId=cab813085e21a, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=来那替尼NERLYNX获NMPA批准，用于HER2阳性乳腺癌患者的延长辅助治疗, objectType=article, longId=193863, objectId=611c193863a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=611c193863a1, replyNumber=0, likeNumber=40, createdTime=2020-05-11, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=611c193863a1, moduleTitle=来那替尼NERLYNX获NMPA批准，用于HER2阳性乳腺癌患者的延长辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=611c193863a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308571, encodeId=cecc13085e16b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, objectType=article, longId=193392, objectId=a9c11933925d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c11933925d, replyNumber=0, likeNumber=29, createdTime=2020-05-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c11933925d, moduleTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c11933925d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308570, encodeId=05fe13085e087, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=崔树德教授专访：HER2阳性乳腺癌治疗生力军 T-DM1降低复发或死亡风险, objectType=article, longId=192917, objectId=4c6e19291ee2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c6e19291ee2, replyNumber=0, likeNumber=37, createdTime=2020-04-26, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c6e19291ee2, moduleTitle=崔树德教授专访：HER2阳性乳腺癌治疗生力军 T-DM1降低复发或死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c6e19291ee2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308569, encodeId=f6a51308569cb, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=18, createdTime=2020-04-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌

2020-12-16

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

突破！乳腺癌疫苗GP2研究发现对HER2阳性乳腺癌术后，5年无一复发！

2020-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌

2020-11-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Clin Cancer Res：Tucatinib获批治疗晚期HER2阳性乳腺癌

2020-10-19

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准

2020-09-06

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

抗体药物偶联物[Vic-]曲妥珠单抗 Duocarmazine治疗HER2阳性实体瘤：已启动I期临床研究

2020-08-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性

2020-08-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌

2020-08-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Nat Commun：HER2阳性乳腺癌在双HER2阻断期间和之后的表型变化

2020-08-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Gastric Cancer：波齐替尼联合紫杉醇和曲妥珠单抗治疗HER2阳性晚期胃癌患者的效果

2020-07-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著

2020-06-20

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌

2020-05-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

范志民教授专访：T-DM1治疗HER2阳性non-pCR乳腺癌面面观

2020-05-23

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2020-05-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-05-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌

2020-05-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

来那替尼NERLYNX获NMPA批准，用于HER2阳性乳腺癌患者的延长辅助治疗

2020-05-11

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

2020-05-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

崔树德教授专访：HER2阳性乳腺癌治疗生力军 T-DM1降低复发或死亡风险

2020-04-26

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2020-04-20

科室
- - 订阅+
  - 更多科室
工具
服务